SENSEX NIFTY
83580.4 25693.7
266.47 (0.32%)
50.90 (0.20%)
 
   A+   I A   I A-   I Skip to main content   I Advisory for investors  I FTP Login   I List of AP  I SMARTODR   I     Webmail

NOTICES

Heading View
  SEBI Circular No. CIR/MRD/DP/01/2014 Dated 7th January, 2014   Click here
  SEBI Circular No. SEBI/HO/MIRSD/MIRSD2/CIR/P/2016/95, Dated 26th September, 2016.   Click here
DETACH
Increase
Minus
Friday, February 6, 2026  SENSEX  : 83580.40  [+266.47]     -  Adani Ports : 1550.20   [-20.70]      Asian Paints : 2402.70   [-29.40]      Axis Bank : 1341.55   [+10.90]      Bajaj Finance : 981.65   [+16.95]      Bajaj Finserv : 2023.95   [+23.45]      Bharat Electron : 429.55   [-3.30]      Bharti Airtel : 2038.35   [+46.30]      Eternal : 283.45   [-3.45]      HCL Technologies : 1593.55   [-15.25]      HDFC Bank : 941.15   [-8.35]      Hind. Unilever : 2423.75   [+69.75]      ICICI Bank : 1406.65   [+10.45]      Infosys : 1506.90   [-12.90]      Interglobe Aviat : 4911.70   [-22.25]      ITC : 326.05   [+15.80]      Kotak Mah. Bank : 422.35   [+13.70]      Larsen & Toubro : 4067.70   [+7.50]      M & M : 3577.65   [+6.25]      Maruti Suzuki : 15001.40   [-49.80]      NTPC : 365.10   [-1.80]      Power Grid Corpn : 292.90   [+3.65]      Reliance Industr : 1450.85   [+7.45]      SBI : 1066.40   [-7.00]      Sun Pharma.Inds. : 1694.70   [-7.60]      Tata Steel : 197.05   [-0.60]      TCS : 2941.45   [-50.60]      Tech Mahindra : 1619.10   [-27.05]      Titan Company : 4141.80   [+43.65]      Trent : 4118.90   [-12.70]      UltraTech Cem. : 12725.50   [-48.85]      
Hot Pursuit Back
Alembic Pharma receives USFDA approval for Parkinson's drug tablets
(06 Feb 2026, 13:12)
The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Stalevo Tablets, manufactured by Orion Corporation. These tablets are indicated for the treatment of Parkinson's disease.

With this approval, Alembic Pharmaceuticals now has a cumulative total of 234 ANDA approvals from the USFDA, including 214 final approvals and 20 tentative approvals.

Alembic Pharmaceuticals, a vertically integrated research and development company, is engaged in the manufacture and marketing of generic pharmaceutical products across global markets.

On the financial front, the company reported a consolidated net profit of Rs 184.71 crore in Q2 FY26, up 20.40% from Rs 153.41 crore in Q2 FY25. Revenue from operations rose 15.90% year-on-year to Rs 1,910.15 crore in the quarter ended September 2025.

Shares of Alembic Pharmaceuticals declined 2.17% to Rs 792.15 on the BSE.

Powered by Capital Market - Live News
 
Attention Investors: No need to issue cheques by investors while subscribing to IPO. just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor’s account. | Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day......................issued in the interest of investors.' "
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
Dear Clients: We are here with requesting you to submit your separate e-mail id to receive communications/reports, by submitting account modification form in this regards or if you have registered your family member e-mail id with us, please submit declaration in this regards. Further, if you have not registered e-mail id/mobile number with us, please register it by submitting account modification form which facilitates you to receive all the data/reports electronically. If you require any clarification, please feel free to call Mr. Hemant Shah on 9004603818 or email us at kyc@swcapital.in
Feedback | Back Office | Downloads | KYC | Disclaimer | Privacy Policy | Investor Grievances |
INVESTOR CHARTER |
INVESTOR CHARTER-STOCK BROKER INVESTOR CHARTER-DEPOSITORY PARTICIPANTS INVESTOR CHARTER–KYC
Communique | Tariff Structure |
INVESTOR COMPLAINTS DETAILS|
Month End Month-Wise Year-Wise

SCORES|
E-Voting Links|
CDSL E-voting NSDL E-voting|
Opening A Account| Filing A Complaints|
SW CAPITAL PVT LTD CIN No. : U67120MH1994PTC081512 | SW Capital Pvt. Ltd.> SEBI Regn. No :- NSE-CM/FO/CD- INZ000182531 | BSE-CM/FO/CD- INZ000182531 | CDSL DP : IN-DP-CDSL-272-2004
Copyright © 2011 -SW Capital Pvt Ltd. All rights reserved. Designed, developed & powered by C-MOTS Infotech (ISO 9001:2015 certified)